Targeted therapies, prognostic and predictive factors in endocrine oncology

Annales d'endocrinologie
S HescotM Lombès

Abstract

A better understanding of molecular mechanisms responsible for tumorigenesis has allowed the development of targeted drugs designed to improve the outcome of cancer. In endocrine tumors, several molecules have demonstrated efficacy in terms of progression free survival during phase III trials such as vandetanib and cabozantinib in medullary thyroid carcinoma, sorafenib in differentiated thyroid carcinoma and everolimus or sunitinib for pancreatic neuroendocrine tumors. Rare cancer network has allowed ongoing phase III trials in malignant pheochromocytoma and adrenocortical carcinoma. However, to date no specific predictive biomarker has yet been identified for a personalized cancer medicine. We review recent advances in endocrine oncology concerning molecular targets identification, targeted therapies and predictive or prognostic markers.

References

Mar 11, 2005·The New England Journal of Medicine·Monika E HegiRoger Stupp
Sep 13, 2006·Virchows Archiv : an International Journal of Pathology·G RindiUNKNOWN European Neuroendocrine Tumor Society (ENETS)
Dec 13, 2007·The Journal of Clinical Endocrinology and Metabolism·Rossella EliseiAldo Pinchera
Nov 13, 2008·The Journal of Clinical Endocrinology and Metabolism·Anthony M JoshuaJennifer J Knox
Jun 9, 2009·Best Practice & Research. Clinical Endocrinology & Metabolism·Jérôme Bertherat, Xavier Bertagna
Nov 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edoardo MissiagliaAldo Scarpa
May 11, 2010·Clinical Oncology : a Journal of the Royal College of Radiologists·S I Sherman
Feb 11, 2011·The New England Journal of Medicine·James C YaoUNKNOWN RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group
Feb 18, 2011·The Journal of Clinical Endocrinology and Metabolism·Margarida M MouraValeriano Leite
Jun 7, 2011·The New England Journal of Medicine·Paul B ChapmanUNKNOWN BRIM-3 Study Group
Jul 26, 2011·Human Molecular Genetics·Nelly BurnichonAnne-Paule Gimenez-Roqueplo
Sep 1, 2011·Nature Reviews. Endocrinology·Yuri E Nikiforov, Marina N Nikiforova
Sep 29, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Martin Schlumberger, UNKNOWN French TUTHYREF Network
Feb 14, 2012·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·A-P Gimenez-RoqueploM Robledo
Jul 28, 2012·The Journal of Clinical Endocrinology and Metabolism·Matthias KroissMartin Fassnacht
Sep 12, 2012·The Journal of Clinical Endocrinology and Metabolism·Montserrat Ayala-RamirezCamilo Jimenez
Nov 20, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A BerrutiUNKNOWN ESMO Guidelines Working Group
Nov 24, 2012·The Journal of Clinical Endocrinology and Metabolism·Victoria M RaymondGary D Hammer
Dec 19, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mohid S KhanTim Meyer
Dec 25, 2012·The Journal of Clinical Endocrinology and Metabolism·Nishant AgrawalDouglas W Ball
Feb 15, 2013·The New England Journal of Medicine·Alan L HoJames A Fagin
Mar 12, 2013·HPB : the Official Journal of the International Hepato Pancreato Biliary Association·Alessandro ZerbiUNKNOWN AISP-Network Study Group
Mar 16, 2013·Thyroid : Official Journal of the American Thyroid Association·Kevin B KimSteven I Sherman
Apr 11, 2013·JAMA : the Journal of the American Medical Association·Mingzhao XingVlasta Sykorova
May 17, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R KurzrockS Sherman
Jun 1, 2013·Endocrine-related Cancer·Giada PoliMichaela Luconi
Jun 8, 2013·The Journal of Clinical Endocrinology and Metabolism·Samuel A WellsMassimo Santoro

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.